Anthony Bajoras

Cellens is a Tufts University spinout startup that is committed to bringing clarity and confidence to patients and physicians through noninvasive cancer detection. We are developing a pipeline of revolutionary noninvasive and accurate at-home and mail-in cancer monitoring tests.

March Biosciences, Inc is a clinical-stage cell therapy company with a mission to transform patient care in the most challenging hematological malignancies. March Bios lead asset is at the end of Phase I trials for T-cell malignancies, diseases with a dismal prognosis that is currently unaddressed by CAR-T and targeted therapy technologies. The companys pipeline is designed to expand on these early successes to more broadly impact other high-challenge cancers.

NXgenPort (NGP) enhances the capabilities of cancer care teams by monitoring their patients remotely. NGP pairs catheter efficacy with new sensor technology and machine learning. Combined, we measure critical physiologic parameters in cancer patients that lead to better outcomes.

Avesta76 Therapeutics is translating a breakthrough in cancer research to clinical application for oncologists and cancer patients worldwide.

AOA Dx is leading a revolutionary breakthrough in early-stage cancer detection, leveraging the transformative potential of AI and our proprietary biomarker technology. At the heart of this innovation is our GlycoLocate platform, a multi-omics approach powered by lipids, metabolites and proteins. This platform is setting a new gold standard in the quest for life-saving early cancer diagnostics. We are now advancing AKRIVIS GD™, a cutting-edge liquid biopsy test designed specifically for the early detection of ovarian cancer.

The NearWave Imager is a revolutionary handheld clinical near-infrared light imaging based device poised to democratize point-of-care diagnostics and imaging in breast cancer.

Reglagene is a therapeutics company that leverages its expertise in the design and development of brain penetrant medicines to create breakthrough therapies for the safe and effective treatment of brain diseases.

Based in metropolitan Phoenix, Arizona, BioAccel is a 501(c)(3) nonprofit organization accelerating the development of new bioscience companies and biomedical products by providing entrepreneurs with the training, mentoring, and support they need to succeed in one of the most heavily regulated and strategically important industries: Biomedical technology. - We seek to develop bioscience entrepreneurs – innovators focused on health informatics and medical devices – to their highest and best potential. - Since our inception in 2009, BioAccel has helped to launch 17 companies and has provided education and mentorship for more than 100 Arizona entrepreneurs. - BioAccel’s portfolio companies support an average wage of $71,800 – 61.8 percent over the Arizona average wage of $44,370. - BioAccel’s entrepreneur accelerator programs have resulted in nearly 100 new, high-paying jobs, expansion of Arizona’s biomedical industry base and a growing entrepreneurial and investment community. From our extensive experience in helping bioscience innovators commercialize their bioscience innovations, we know that many entrepreneurs do not have a clear understanding of the commercialization continuum for biomedical technologies. That’s why our workshops and personal guidance include a proof-of-concept program that addresses the challenges of technology commercialization. Our goal is to increase the pipeline of high-potential proof-of-concept projects and assist with the due diligence required to launch successful bioscience companies in Arizona.

Cellens is a Tufts University spinout startup that is committed to bringing clarity and confidence to patients and physicians through noninvasive cancer detection. We are developing a pipeline of revolutionary noninvasive and accurate at-home and mail-in cancer monitoring tests.

March Biosciences, Inc is a clinical-stage cell therapy company with a mission to transform patient care in the most challenging hematological malignancies. March Bios lead asset is at the end of Phase I trials for T-cell malignancies, diseases with a dismal prognosis that is currently unaddressed by CAR-T and targeted therapy technologies. The companys pipeline is designed to expand on these early successes to more broadly impact other high-challenge cancers.

NXgenPort (NGP) enhances the capabilities of cancer care teams by monitoring their patients remotely. NGP pairs catheter efficacy with new sensor technology and machine learning. Combined, we measure critical physiologic parameters in cancer patients that lead to better outcomes.

Avesta76 Therapeutics is translating a breakthrough in cancer research to clinical application for oncologists and cancer patients worldwide.